曲妥珠单抗联合紫杉醇治疗对转移性乳腺癌患者血清CEA、CA-125及CA15-3的影响

摘要

Objective To investigate the effect of trastuzumab combined with paclitaxel on serum carcinoembryonic antigen (CEA),carbohydrate antigen (CA-125) and carbohydrate antigen (CA15-3) in patients with metastatic breast cancer.Methods 80 patients with metastatic breast cancer in our hospital from March 2014 to March 2016 served as the research objects.The clinical data were retrospectively analyzed in this study.The patients were divided into observation group and control group.The observation group (40 patients) was treated with trastuzumab combined with paclitaxel treatment.The control group (40 patients) were treated with simple trastuzumab The serum CEA,CA-125 and CA15-3,the influence of short-term clinical efficacy and adverse reaction conditions were analyzed.Results Serum CEA,CA-125 and CA15-3 levels of the two groups before and after treatment were significantly different.The serum CEA,CA-125 and CA15-3 levels of the observation group after treatment were significantly lower than that of the control group (P＜0.05).The efficiency rate of observation group (70％) was significantly higher than that of the control group (47.5％) (P＜ 0.05).The adverse reactions included rash,nausea and vomiting,neutropenia and diarrhea.The incidence of the adverse reaction rate in the observation group and the control group were 32.5％ and 27.5％ (P＞ 0.05).Conclusion The trastuzumab in combination with paclitaxel can effectively reduce serum CEA,CA-125 and CA15-3 levels of patients with metastatic breast cancer,play a synergistic effect,have less side effects and reduce the risk of adverse events.%目的 探讨曲妥珠单抗联合紫杉醇对转移性乳腺癌患者血清癌胚抗原(CEA)、糖类抗原(CA-125)及糖类抗原(CA15-3)的影响.方法 选择我院2014年3月～2016年3月接诊的80例转移性乳腺癌患者作为研究对象,对患者的临床资料进行回顾性分析,本次研究采用随机数表法将患者均分为两组,即分为观察组和对照组各40例.观察组采用曲妥珠单抗联合紫杉醇进行治疗;对照组采用单纯的曲妥珠单抗进行治疗.经过治疗后对比分析两组不同的治疗方案对早期转移性乳腺癌患者血清CEA、CA-125及CA15-3的影响、近期临床疗效以及不良反应情况.结果 两组治疗前后的血清CEA、CA-125及CA15-3水平差异变化明显,并且观察组治疗后的血清CEA、CA-125及CA15-3水平明显低于对照组,差异有统计学意义(P＜0.05);治疗后,与对照组相比,观察组有效率高,差异有统计学意义(10％ vs47.5％,P＜0.05);两组患者的不良反应比较差异无统计学意义(32.5％ vs 27.5％,P＞0.05).结论 临床治疗转移性乳腺癌患者,使用曲妥珠单抗联合紫杉醇方案,可以有效降低患者血清CEA、CA-125及CA15-3水平,两种药物联合使用能发挥协同作用,副作用较小,不良反应发生的几率较低,并且可控,值得临床推广使用.